Skip to content

the effect of ischemia/reperfusion injuries by pringle manoeuvre on the prognosis of hepatocellular carcinoma patients after radical excision

the effect of ischemia/reperfusion injuries elicited by pringle manoeuvre on the prognosis of hepatocellular carcinoma patients after radical excision: a multicenter prospective randomized study

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-08000129
Enrollment
Unknown
Registered
2008-07-23
Start date
2008-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heptitis virus B related primary hepatocellular carcinoma

Interventions

Control group:Liver cancer radical cure by ischemia injuries by
Experimental group:Liver cancer radical cure treatment by pringle manoeuvre.

Sponsors

Institute of Hepatobiliary Surgery, Southwest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 18 to 65 years, without gender restriction; 2. Clinical diagnosis of resectable primary liver cancer; 3. The liver function tests showed: Child-Pugh grade A; clearance of indocyanine green at 15 minutes (CICG-R15) of 20%; 4. Hepatitis B surface antigens (HBsAg)positive,hepatitis B deoxyribonucleic acid (HBV-DNA) less than 100000 copies/ml; 5. No more than two tumour nodes in the liver; 6. No preoperative anti-cancer therapy; 7. Written informed consent from the patient or legal guardian prior to entering the study.

Exclusion criteria

Exclusion criteria: 1. Patients with pregnancy; 2.with extrahepatic tumor or lymphnode metastasis; 3.tumor invasion or thrombosis in portal vein,hepatic vein or inferior vena cava; 4.positive surgical margin.

Design outcomes

Primary

MeasureTime frame
Survival without cancer;Survival;Recurrence of liver cancer;Mortality;

Countries

China

Contacts

Public ContactDong Jiahong, Wang Shuguang
xiaobinf@medmail.com.cn+86 023 68754168

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026